

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-33. (Cancelled)

34. (New) A substantially pure mycoplasma polypeptide of a pathogenic *Mycoplasma hyopneumoniae*, wherein said mycoplasma polypeptide increases calcium release from porcine ciliated tracheal cells.

35. (New) The polypeptide of claim 34, wherein said mycoplasma polypeptide is obtained from pathogenic *Mycoplasma hyopneumoniae*.

36. (New) The polypeptide of claim 34, wherein said mycoplasma polypeptide is about 80 percent pure.

37. (New) The polypeptide of claim 34, wherein said mycoplasma polypeptide is about 90 percent pure.

38. (New) The polypeptide of claim 34, wherein the molecular weight of said mycoplasma polypeptide following a tryptic digest is between about 10 kDa and about 80 kDa.

39. (New) A substantially pure antibody capable of binding a mycoplasma polypeptide of a pathogenic *Mycoplasma hyopneumoniae*, wherein said mycoplasma polypeptide increases calcium release from porcine ciliated tracheal cells.

40. (New) The antibody of claim 39, wherein said antibody is a monoclonal antibody.
41. (New) The antibody of claim 39, wherein said antibody is a mouse antibody.
42. (New) The antibody of claim 39, wherein said mycoplasma polypeptide is obtained from pathogenic *Mycoplasma hyopneumoniae*.
43. (New) The antibody of claim 39, wherein said antibody is about 80 percent pure.
44. (New) The antibody of claim 39, wherein said antibody is about 90 percent pure.
45. (New) The antibody of claim 39, wherein the molecular weight of said mycoplasma polypeptide following a tryptic digest is between about 10 kDa and about 80 kDa.
46. (New) A method for inducing an immune response in a mammal, wherein said immune response is against a mycoplasma polypeptide of a pathogenic *Mycoplasma hyopneumoniae*, said method comprising administering a substantially pure mycoplasma polypeptide of a pathogenic *Mycoplasma hyopneumoniae* to said mammal under conditions wherein said mammal produces antibodies against said mycoplasma polypeptide, wherein said mycoplasma polypeptide increases calcium release from porcine ciliated tracheal cells.
47. (New) The method of claim 46, wherein said mammal is a mouse, rabbit, or pig.
48. (New) The method of claim 46, wherein the molecular weight of said mycoplasma polypeptide following a tryptic digest is between about 10 kDa and about 80 kDa.

49. (New) A method for binding an antibody to a mycoplasma polypeptide of a pathogenic *Mycoplasma hyopneumoniae*, wherein said mycoplasma polypeptide increases calcium release from porcine ciliated tracheal cells, said method comprising:

- a) obtaining an antibody capable of binding said mycoplasma polypeptide, and
- b) contacting said antibody with said mycoplasma polypeptide under conditions wherein said antibody binds said mycoplasma polypeptide.

50. (New) The method of claim 49, wherein said antibody is a monoclonal antibody.

51. (New) The method of claim 49, wherein said antibody is a mouse antibody.

52. (New) The method of claim 49, wherein the molecular weight of said mycoplasma polypeptide following a tryptic digest is between about 10 kDa and about 80 kDa.

53. (New) A method for identifying an inhibitor of mycoplasma induced calcium release from cells, said method comprising:

- a) contacting cells with a mycoplasma polypeptide of a pathogenic *Mycoplasma hyopneumoniae* and a test compound, wherein said mycoplasma polypeptide increases calcium release from porcine ciliated tracheal cells,
- b) determining whether said test compound inhibits said cells from releasing calcium, wherein inhibition of calcium release from said cells by said test compound indicates that said test compound is said inhibitor.

54. (New) The method of claim 53, wherein said test compound is a protease.

55. (New) The method of claim 53, wherein said test compound is an antibody.

56. (New) The method of claim 53, wherein the molecular weight of said mycoplasma polypeptide following a tryptic digest is between about 10 kDa and about 80 kDa.

57. (New) A method for identifying an inhibitor of calcium release from cells induced by a mycoplasma polypeptide of a pathogenic *Mycoplasma hyopneumoniae*, wherein said mycoplasma polypeptide increases calcium release from porcine ciliated tracheal cells, said method comprising:

- a) contacting cells with a mycoplasma polypeptide of a pathogenic *Mycoplasma hyopneumoniae* pretreated with a test compound, and
- b) determining whether said test compound inhibits said cells from releasing calcium, wherein inhibition of calcium release from said cells by said test compound indicates that said test compound is said inhibitor.

58. (New) The method of claim 57, wherein said test compound is a protease.

59. (New) The method of claim 57, wherein said test compound is an antibody.

60. (New) The method of claim 57, wherein the molecular weight of said mycoplasma polypeptide following a tryptic digest is between about 10 kDa and about 80 kDa.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.